Enquiries Open · Genome Valley Phase III · Hyderabad

Purpose-built
manufacturing space
for life sciences
in India

Shell-and-core and build-to-suit manufacturing facilities on a 2.3-acre site in India's only manufacturing-zoned area of Genome Valley. Designed for established pharma, biotech, CDMO and medical device companies — domestic and international.

Site Overview Enquiries Open
Total land available2.3 Acres
ZoningManufacturing only
ClusterGenome Valley Phase III
Land secured viaTSIIC (Government)
Sponsor occupancy10,000 sq ft (retained)
Available to tenantUp to ~90,000 sq ft
Fit-out modelShell-and-core / BTS
Statutory approvals15-day guarantee
Phase III — Manufacturing Zone Only The only manufacturing-designated area within Genome Valley. TSIIC does not regularly release plots of this type. Enquiries are welcome now.

Available Space

2.3 Acres of Manufacturing-Zoned Land
in Genome Valley Phase III

We are retaining 10,000 sq ft for our own operations. The remaining site — across the existing one-acre plot and an adjacent 1.3-acre plot available exclusively to us — is offered on long-term lease terms, shell-and-core or turnkey to your specification.

An Exceptionally Rare Opportunity
Zoned biotech and pharmaceutical manufacturing space in Genome Valley Phase III is not readily available. Phase III is the only manufacturing-designated zone within the entire Genome Valley cluster — TSIIC does not regularly release plots of this type to the open market. Companies seeking to establish a manufacturing presence in Genome Valley typically face a years-long wait, or are forced to locate on less strategically situated land elsewhere in Telangana. This site represents one of very few direct opportunities to secure a land position in India's premier life sciences district.
Available · Plot A
~25,000 sq ft
Unit A — Acre One
Remaining buildable capacity on the existing site. Available shell-and-core for self-fit, or delivered as a fully fitted turnkey cleanroom-ready facility.
Shell-and-core or Turnkey GMP / US FDA / WHO From 2026
View Full Details
Build-to-Suit / Lease · Plot B
1.3 acres
Unit B — Adjacent Plot
Exclusively available adjacent 1.3-acre plot. Ideal for a dedicated manufacturing campus — shell-and-core lease or full purpose-built facility designed entirely to your brief.
Shell-and-core or Purpose-built ~55,000–65,000 sq ft Dedicated site
View Full Details

Who We Suit

Built for Established Life Sciences Manufacturers

We suit both established domestic pharma companies looking for a shell-and-core finish they can fit out to their own standard, and international companies that want a fully turnkey, cleanroom-ready, manufacturing-ready solution from day one.

💊
Pharmaceutical Manufacturers

Finished dosage form, API, or specialty pharma companies requiring GMP-compliant manufacturing space. Shell-and-core delivery allows you to fit out fully to your regulatory standard — US FDA, EU GMP, or WHO — without compromise.

Finished dosage / API / formulation Clean room builds to tenant spec US FDA / EU GMP / WHO compliant Domestic Indian and international
🏭
CDMOs & Contract Manufacturers

Contract development and manufacturing organisations expanding capacity in India's most cost-competitive cluster. Genome Valley's dense pharma ecosystem gives immediate access to raw material suppliers, API producers and established logistics networks.

Multi-product manufacturing layouts Proximity to raw material suppliers Established freight and logistics Build-to-suit for complex operations
🌐
International Companies Entering India

European, US, Japanese and other international life sciences companies establishing their first India manufacturing base. Most companies build their own premises because no specialist developer meets this demand — we do. Full local support for regulatory, statutory and operational requirements is included.

No capital diversion from core operations Local regulatory navigation included TS-iPASS 15-day approval guarantee Telangana Life Sciences Policy incentives
🔬
Biotech & Medical Devices

Biotech companies requiring specialist manufacturing environments — biosafety, containment, specialist HVAC — or medical device manufacturers scaling production in India. The 1.3-acre adjacent plot enables full customisation of a purpose-built, standalone facility to your exact technical brief.

Specialist environment builds available Biosafety / containment / HVAC Medical device manufacturing Dedicated plot — full design control
📋
How Indian life sciences real estate works — a note for international companies
Unlike Western markets where landlords provide fitted laboratories, established Indian life sciences tenants typically invest heavily in their own equipment and fit-out. This creates longer, more resilient leases — often 10 years or more — because tenants are bound to their space by both capital investment and licensing obligations. We deliver shell-and-core with GMP-ready building fabric; you own your fit-out and your process environment. This is the market standard, and the most capital-efficient model for serious manufacturers entering India.

Why Hyderabad

The World's Most Competitive Life Sciences Manufacturing Base

Hyderabad is ranked by CBRE as one of the world's top seven life sciences clusters — alongside Boston, San Francisco, Oxford and Cambridge. It is India's fastest-growing life sciences hub, and the only city in Asia Pacific with both the manufacturing scale and the cost structure to compete directly with Western clusters.

01 —
£0.06–0.07
Industrial Power (per kWh)
3–4× lower than Boston. 4–5× lower than Oxford and San Francisco. Energy is the single largest variable operating cost in pharmaceutical manufacturing.
02 —
£14,000
Quality Manager Salary (Annual)
10–15× more competitive than equivalent US and UK roles. Deep, highly skilled workforce with 250,000+ STEM graduates annually from Hyderabad's universities.
03 —
23%
Hyderabad Life Sciences Growth Rate
Hyderabad's life sciences sector is expanding at 23% — significantly faster than the Indian national average of 14% — driven by global supply chain investment and regulatory expansion.
04 —
Global Vaccine Output
Hyderabad produces approximately one third of global vaccine output, cementing its status as the world's vaccine capital. Home to Bharat Biotech, Biological E, and the Serum Institute supply chain.
05 —
200+
Companies in Genome Valley
GSK, Novartis, Sanofi, BMS, Ferring, Eurofins and 200+ others already established. 2,000 acres of cluster infrastructure with 2.5M sq ft of existing lab and manufacturing space.
06 —
5.8M
Sq Ft Leased in 2024
Life sciences companies leased 5.8 million sq ft of space across India in 2024 — a 56% increase on 2023. Demand is running well ahead of available supply.
07 —
$9.7B
Pharma City Investment Pipeline
Hyderabad Pharma City — the world's largest integrated pharma park at 19,000 acres — is under development and expected to attract $9.7 billion in investment, sustaining long-term demand for manufacturing space.
08 —
15 days
Statutory Approvals via TS-iPASS
"Right to Clearance" law guarantees approvals within 15 days. 20+ years of uninterrupted Telangana government policy support for life sciences investment with a dedicated Life Sciences Policy 2023–2028.
Recent Investment Signals
Eli Lilly
Committed $1 billion to establish its first India manufacturing hub in Hyderabad — its largest facility outside the US
Advent International
Deployed $2 billion to acquire and consolidate Hyderabad-based pharma firms into the Cohance CDMO platform
Bristol Myers Squibb
Opened a $100M+ Global Drug Development Centre employing 1,500 scientists — their largest R&D presence outside the US
Eurofins Scientific
Established a 90,000 sq ft laboratory campus in Genome Valley for pharma analytics, bioanalytics and toxicology
Takeda / Biological E
Partnership to manufacture 50 million dengue vaccine doses per year from Genome Valley
Laurus Labs / Krka
€50M joint venture for finished dosage manufacturing in Hyderabad
Global Cluster Industrial Power Quality Manager
★ Hyderabad £0.06–0.07 / kWh £14,000 / yr
Toronto £0.06–0.07 / kWh £55,100 / yr
Shanghai / Beijing £0.07–0.08 / kWh £13,300–50,200 / yr
Oxford £0.26–0.28 / kWh £49,200 / yr
Boston £0.14–0.15 / kWh £152,000 / yr
San Francisco £0.20–0.21 / kWh £135,900 / yr

The Team

Who You Are Working With

Three principals with complementary expertise across international business development, Hyderabad operations, and on-the-ground project delivery. All three are also directly involved in building Patch House Labs — a transdermal pharmaceutical manufacturing business — on the existing site, giving us hands-on, day-one knowledge of what it takes to establish a GMP manufacturing operation in Genome Valley Phase III.

Isaac Davidson
Founder & Managing Director
Isaac Davidson

Isaac is the UK-based founder and originator of the Genome Valley Phase III opportunity. He leads international business development and is the primary point of contact for all tenant enquiries — from initial conversation through to heads of terms. Isaac identified and secured the Phase III land through TSIIC and structures the SPV and commercial arrangements for incoming tenants.

He is also the founder of Patch House Labs India, the transdermal manufacturing business being built on the existing site — giving him direct experience of navigating the full development process from land acquisition to GMP fit-out.

Tenant Relations International BD SPV Structuring Land Acquisition
Vamsi Somanchi
Operations Director — Hyderabad
Vamsi Somanchi

Vamsi is the Hyderabad-based Operations Director, overseeing all in-country activity across the site. His most significant asset is a direct relationship with the Telangana State Industrial Infrastructure Corporation (TSIIC) — the government body that controls land allocation in Genome Valley — which underpins our ability to offer the adjacent 1.3-acre plot on the same acquisition terms.

Vamsi manages contractor relationships, construction programme oversight, and the commercial and operational set-up of Patch House Labs India, where he holds an equity stake. His network within the Hyderabad life sciences community is central to our local execution capability.

Hyderabad Operations TSIIC Relations Construction Management Government Liaison
Gopi — Project Manager
Senior Project Manager — On-Site
Gopi

Gopi is our experienced on-the-ground project manager, embedded full-time at the Phase III site. He brings deep knowledge of the local regulatory environment and has established working relationships with the authorities responsible for manufacturing licences, mains utility connections — power, water, and drainage — and operational clearances required to bring a facility into use.

His experience navigating TS-iPASS approvals and local statutory processes means that timelines and costs are known quantities rather than estimates. Gopi is also directly managing the construction and fit-out of Patch House Labs India on the existing site.

Regulatory Licences Mains Connections TS-iPASS Site Management Contractor Networks
🏭
Patch House Labs India — Built on This Site
All three principals are currently building Patch House Labs India — a GMP transdermal pharmaceutical manufacturing business — on the existing 10,000 sq ft unit on Acre One. This means we are not property developers in the abstract: we are operators navigating the same regulatory environment, the same contractors, the same utility connections, and the same approval processes that any incoming tenant will face. That experience is directly available to you.

Location

Genome Valley Phase III — Karkapatla, Medak

The site sits within the Biotech Park Phase III development at Karkapatla Village, Mulugu Mandal, Medak District — approximately 45km north of Hyderabad city centre and 35km from Rajiv Gandhi International Airport. Phase III is the manufacturing-designated extension of the Genome Valley cluster, directly adjacent to existing SEZ and non-SEZ biotech operations.

Site Address
Karkapatla Village, Mulugu Mandal, Medak District, Telangana
Distance to Hyderabad City
~45km via NH 44 (approx. 50 min)
Distance to Airport (RGIA)
~35km (approx. 40 min)
Cluster
Genome Valley — India's largest life sciences cluster
Land Authority
TSIIC — Telangana State Industrial Infrastructure Corporation
Zoning
Manufacturing Zone (Phase III exclusive designation)
Surrounding Infrastructure
30m wide arterial roads, green belts, CETP, substation, SEZ zones
Nearest Major Companies
Novartis, GSK, Sanofi, Eurofins, BMS — all within Genome Valley cluster

How It Works

From First Conversation to Operational Facility

We provide a direct, low-friction pathway for companies to assess requirements, agree terms, and begin manufacturing in Hyderabad — without the delays and capital diversion of a self-build programme.

01
Initial Enquiry
Submit your requirements. We respond within 48 hours with a tailored site overview.
02
Requirements Call
Structured conversation covering space, technical brief, regulatory standards, timeline and lease expectations.
03
Site Proposal
Detailed layout options, shell-and-core or BTS configurations, indicative lease terms and pricing.
04
Site Visit
Hosted visit to Genome Valley Phase III with introductions to regulatory contacts, contractors and local partners.
05
Heads of Terms
Formalise the lease, begin construction planning. TS-iPASS approvals guaranteed within 15 days.

Enquire

Tell Us What You Need

We work with a focused number of tenants to ensure each project receives dedicated attention. Share your requirements and we will respond within 48 hours.

Most life sciences companies in India build their own premises because no specialist developer is meeting the demand. We are here to change that — providing the space, the expertise, and the local relationships so you can focus entirely on your manufacturing operations.

Location
Genome Valley Phase III, Shameerpet, Hyderabad, Telangana
Email
Response Time
Within 48 business hours

Enquiry

Tell us about your company and space requirements. All enquiries are treated in strict confidence.

All enquiries are treated in strict confidence. We do not share your details with third parties.